2025
Nordyke RJ , Patterson JA, Motyka J, March B, Kirson NY, Long G. 2025. The impact of the Inflation Reduction Act’s drug price negotiation program on incentives for clinical development of new drugs. Value Health; doi: 10.1016/j.jval.2025.08.011 . Online ahead of print Sept. 1, 2025. PMID: 40902797.
View Abstract
Topics: drug development
Proctor D, Jiang X, Reichert H , Thompson C. 2025. Why rat oral cavity tumors should not be the basis of quantitative cancer risk assessment for oral exposure to hexavalent chromium. Toxicol Sci kfaf112; doi: 10.1093/toxsci/kfaf112 . Online ahead of print August 8, 2025. PMID: 40795394.
View Abstract
Topics: Cancer , chromium , Exposure Assessment , risk assessment
Clouser MC, Suh M , Movva N , Hildebrand JS, Pastula ST, Schoehl M, Hindoyan A, Balasubramanian A, et al. 2025. A systematic literature review of MTAP deletions in solid and hematologic cancers. Cancer Treat Res Comm 44:100966; doi: 10.1016/j.ctarc.2025.100966 . PMID: 40729867.
View Abstract
Topics: Cancer , Systematic Review
Allen BC, Vincent MJ, Lipworth L, Panko JM, Suh M, Jiang X , Mumma MT, Proctor DM. 2025. Lung cancer risk assessment associated with exposure to hexavalent chromium: Results of pooled analysis of three cohorts. J Occup Environ Hyg; doi: 10.1080/15459624.2025.2502491 . Online ahead of print May 28, 2025. PMID: 40435461.
View Abstract
Topics: Cancer , chromium , Exposure Assessment , risk assessment
Duong T, Haselkorn T, Miller B, Coats J, Jensen I , Ward E, Wood M, Graham RJ, Servais L. 2025. A real-world analysis of the impact of X-linked myotubular myopathy on caregivers in the United States. Orphanet J Rare Dis 20(1):224. doi: 10.1186/s13023-025-03583-w .
View Abstract